Pfizer will charge US$110 to US$130 for a dose of its COVID-19 vaccine once the U.S. government stops buying the shots, but the drugmaker says it expects many people will continue receiving it for free.
Pfizer executives said the commercial pricing for adult doses could start early next year, depending on when the government phases out its program of buying and distributing the shots.
The drugmaker said it expects that people with private health insurance or coverage through public programs like Medicare or Medicaid will pay nothing. The Affordable Care Act requires insurers to cover many recommended vaccines without charging any out-of-pocket expenses.
A spokesman said the company also has an income-based assistance program that helps eligible U.S. residents with no insurance get the shots.
The price would make the two-dose vaccine more expensive for cash-paying customers than annual flu shots. Those can range in price from around US$50 to US$95, depending on the type, according to CVS Health, which runs one of the nation's biggest drugstore chains.
A Pfizer executive said Thursday that the price reflects increased costs for switching to single-dose vials and commercial distribution. The executive, Angela Lukin, said the price was well below the thresholds "for what would be considered a highly effective vaccine."
The drugmaker said last year that it was charging the U.S. US$19.50 per dose, and that it had three tiers of pricing globally, depending on each country's financial situation. In June, the company said the U.S. government would buy an additional 105 million doses in a deal that amounted to roughly US$30 per shot. The government has the option to purchase more doses after that.
Pfizer's two-shot vaccine debuted in late 2020 and has been the most common preventive shot used to fight COVID-19 in the U.S.
More than 375 million doses of the original vaccine, which Pfizer developed with the German drugmaker BioNTech, have been distributed in the U.S., according to the Centers for Disease Control and Prevention.
That doesn't count another 12 million doses of an updated booster that was approved earlier this year.
The vaccine brought in US$36.78 billion in revenue last year for Pfizer and was the drugmaker's top-selling product.
Analysts predict that it will rack up another US$32 billion this year, according to FactSet. But they also expect sales to fall rapidly after that.
More than 90 per cent of the adult U.S. population has already received at least one dose of COVID-19 vaccine, according to the CDC. But only about half that population has also received a booster dose.
------
The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute's Department of Science Education. The AP is solely responsible for all content.
